Cognition Therapeutics CEO Excited for Upcoming Conferences

Cognition Therapeutics Leadership at Healthcare Conferences

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a pioneering biopharmaceutical company dedicated to developing therapies for neurodegenerative disorders, is excited to announce that its CEO, Lisa Ricciardi, will participate in significant healthcare conferences soon. These events are pivotal for the company as they coincide with the annual JP Morgan Healthcare Conference.

Progress in Alzheimer’s and Neurodegenerative Research

In her recent statements, Ms. Ricciardi expressed enthusiasm about discussing the remarkable strides made during the previous year concerning their Alzheimer's and Dementia with Lewy Body (DLB) programs. Notably, 2024 was a defining year for Cognition Therapeutics as they marked the successful completion of their Phase 2 SHIMMER study, yielding promising topline results for DLB patients. This achievement propels them towards presenting their findings at the upcoming International Lewy Body Dementia Conference, set to be held in late January.

Upcoming Presentations

Beyond the conference presentations, Cognition's leadership is also preparing for a pivotal end-of-Phase 2 meeting with the FDA to review results from their SHINE study, which focuses on mild to moderate Alzheimer's disease. This meeting represents a critical milestone for regulatory and development strategies. Furthermore, the company has received clearance for the generic name of its neurodegenerative drug candidate, which will now be known as zervimesine.

Details of Conference Participation

Here are some crucial details regarding the conferences where Ms. Ricciardi will present:

Longwood Healthcare Leaders Stanford Summit

Date: January 11, 2025
Panel: Accelerating Drug Development
Location: The Four Seasons, San Francisco, CA

Sachs 8th Annual Neuroscience Innovation Forum

Date: January 12, 2025
Panel: Innovation in AD/PD & Other Cognitive Disorders
Corporate Presentation: 1:40 PM Track C Heritage Room
Location: Marines' Memorial Club, San Francisco, CA

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. specializes in discovering and developing groundbreaking small molecule therapeutics aimed at age-related neurodegenerative disorders affecting the central nervous system and retina. Currently, they are focused on their lead candidate, zervimesine (formerly known as CT1812), which is being investigated in clinical trials for Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration (dry AMD). The company believes that their unique approach utilizing ?-2 receptor modulators offers new strategies to regulate the disrupted pathways associated with these conditions.

Vision for the Future

Cognition Therapeutics aims to continue its innovative trajectory by advancing its clinical programs that could significantly impact the treatment landscape for neurodegenerative diseases. The company is committed to improving patient outcomes through dedicated research and development efforts.

Frequently Asked Questions

What is Cognition Therapeutics working on?

The company focuses on developing treatments for Alzheimer's disease, dementia with Lewy bodies, and other related cognitive disorders.

What is the significance of zervimesine?

Zervimesine is Cognition's lead candidate, targeting pathways impaired in neurodegenerative conditions. It was previously known as CT1812.

When will Cognition Therapeutics present their findings?

They are set to present at the International Lewy Body Dementia Conference later this month and participate in various panels at upcoming healthcare conferences.

Who is the CEO of Cognition Therapeutics?

Lisa Ricciardi is the CEO, and she will be representing the company at major health conferences this January.

What are the upcoming events Cognition Therapeutics is attending?

The company will participate in the Longwood Healthcare Leaders Stanford Summit and the Sachs 8th Annual Neuroscience Innovation Forum.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.